TARS Tarsus Pharmaceuticals, Inc.
$75.69
Tarsus Pharmaceuticals, Inc. (TARS) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $1.49 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +31.3% since its last earnings release on August 6, 2026.
Tarsus Pharmaceuticals, Inc. Missed Consensus Estimates
Thursday, August 6, 2026 · 7:03 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · After Close
Earnings Whisper
-
vs ($1.49)
Rev est $183.28M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$75.80
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.